Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 1/2013

01-01-2013 | Original article

Influence of osteopontin silencing on survival and migration of lung cancer cells

Authors: B. Polat, MD, G. Wohlleben, A. Katzer, C.S. Djuzenova, A. Technau, M. Flentje

Published in: Strahlentherapie und Onkologie | Issue 1/2013

Login to get access

Abstract

Background and purpose

Osteopontin (OPN) is a multifunctional protein overexpressed in many cancers and is involved in tumor progression and metastasis. In lung cancer, elevated OPN expression is associated with an unfavorable prognosis. Therefore, inhibition of OPN is an attractive approach for improving survival.

Materials and methods

We used siRNA to specifically downregulate OPN expression in A549 lung cancer cells. OPN silencing was evaluated with quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for mRNA levels and with Western blotting for protein levels. Effects on cell proliferation were measured by cell counting. The influence on tumor cell migration was detected using a modified Boyden chamber. Changes in cell cycle distribution were assessed by flow cytometry. Using the colony formation assay, we determined changes in radiosensitivity.

Results

A specific and effective downregulation of OPN expression was detected in both RNA and protein levels. Cell proliferation and cell migration were significantly reduced by OPN silencing after 24 h and the effects were further increased by the addition of irradiation. The cell cycle distribution showed a reduction in S phase and an increase in cells arrested in both G0/G1 and G2/M phases. Specific enhancement of radiosensitivity was clearly shown after OPN knockdown.

Conclusion

The combination of OPN silencing and irradiation showed a synergistic effect leading to reduced cell survival.
Literature
1.
Bache M, Reddemann R, Said HM et al (2006) Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 66:1481–1487PubMedCrossRef
2.
Bayer C, Vaupel P (2012) Acute versus chronic hypoxia in tumors: controversial data concerning time frames and biological consequences. Strahlenther Onkol 188:616–627PubMedCrossRef
3.
Bellahcene A, Castronovo V, Ogbureke KU et al (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nature reviews. Cancer 8:212–226PubMed
4.
Blasberg JD, Pass HI, Goparaju CM et al (2010) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28:936–941PubMedCrossRef
5.
Boldrini L, Donati V, Dell’Omodarme M et al (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRef
6.
Chambers AF, Wilson SM, Kerkvliet N et al (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRef
7.
Chang SH, Minai-Tehrani A, Shin JY et al (2012) Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin. J Radiat Res
8.
Chong HC, Tan CK, Huang RL et al (2012) Matricellular proteins: a sticky affair with cancers. J Oncol 351089
9.
Courter D, Cao H, Kwok S et al (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PloS one 5:e9633PubMedCrossRef
10.
Djuzenova C, Muhl B, Schakowski R et al (2004) Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients. Br J Cancer 90:2356–2363PubMed
11.
Fong YC, Liu SC, Huang CY et al (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64:263–270PubMedCrossRef
12.
Goparaju CM, Pass HI, Blasberg JD et al (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5:1516–1523PubMedCrossRef
13.
Hahnel A, Wichmann H, Kappler M et al (2010) Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 5:82PubMedCrossRef
14.
Isa S, Kawaguchi T, Teramukai S et al (2009) Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4:1104–1110PubMedCrossRef
15.
Le QT, Chen E, Salim A et al (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12:1507–1514PubMedCrossRef
16.
Lukacova S, Overgaard J, Alsner J et al (2006) Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiother Oncol 80:165–171PubMedCrossRef
17.
Mack PC, Redman MW, Chansky K et al (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771–4776PubMedCrossRef
18.
Maftei CA, Bayer C, Shi K et al (2011) Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques. Strahlenther Onkol 187:260–266PubMedCrossRef
19.
Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757–764PubMedCrossRef
20.
Said HM, Hagemann C, Staab A et al (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83:398–405PubMedCrossRef
21.
Said HM, Katzer A, Flentje M et al (2005) Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol 76:200–205PubMedCrossRef
22.
Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252–259PubMedCrossRef
23.
Wu J, Pungaliya P, Kraynov E et al (2012) Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 17:125–133PubMedCrossRef
24.
Yang L, Zhao W, Zuo WS et al (2012) Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Chin Med J (Engl) 125:293–299
25.
Zhao B, Sun T, Meng F et al (2011) Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137:1061–1070PubMedCrossRef
26.
Zhu Y, Denhardt DT, Cao H et al (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555–6563PubMed
Metadata
Title
Influence of osteopontin silencing on survival and migration of lung cancer cells
Authors
B. Polat, MD
G. Wohlleben
A. Katzer
C.S. Djuzenova
A. Technau
M. Flentje
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 1/2013
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0238-5

Other articles of this Issue 1/2013

Strahlentherapie und Onkologie 1/2013 Go to the issue

Original article

A validated survival score for breast cancer patients with metastatic spinal cord compression

Original article

Accurate estimation of dose distributions inside an eye irradiated with 106Ru plaques

Literatur kommentiert

Screening von Genpolymorphismen verbessert die Vorhersage der Strahlentoxizität nicht

Original article

Benefit of replacing the Sigma-60 by the Sigma-Eye applicator

Original article

Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer

Original article

Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute